3 interventions in Pharmaceutical graded Proven in humans.
GLP-1 Receptor Agonists (Semaglutide, Tirzepatide)
Genuinely transformative cardiometabolic drugs with real mortality-relevant benefit in people with excess weight, but they are not validated longevity agents, and muscle loss plus lack of aging-specific outcome data temper the 'anti-aging miracle' framing. Powerful for the right person, not a geroprotector for the lean and healthy.
SGLT2 Inhibitors (Canagliflozin, Empagliflozin, Dapagliflozin)
Real, hard-endpoint mortality benefit in sick populations (heart/kidney disease) and a striking male-mouse lifespan result, but the sex-specific animal effect and lack of any healthy-human aging trial mean the leap to 'longevity drug for the well' is unearned.
Statins (in a Longevity Context)
Genuinely life-saving for cardiovascular risk, and preventing the #1 killer buys years, but that is targeted disease prevention, not aging modulation. Calling statins a 'longevity drug' conflates two different things: they lengthen life by stopping heart attacks, not by slowing the aging process.